In response to concerns about diphtheria vaccine efficacy, a case-control study was undertaken in Ukraine in 1996 to determine whether those recently immunized were indeed protected from disease, whether multiple doses were more protective, whether contact with children was related to disease, and whether there were detectable differences in protective efficacy between Western and Russian vaccines. In each of the three sites (one rural and two urban), 60 adults with laboratory-confirmed cases of diphtheria were identified from health center records along with 2 adult controls, who were matched to the case by neighborhood. Demographic and vaccination data were gathered from health center records. Using conditional logistic regression to estimate odds ratios, it was determined that cases were more likely to have had no vaccine in the year prior to the index data (odds ratio, 5.0; 95% confidence interval, 2.8-9.0), for a vaccine efficacy of 80%. Two doses gave greater protection, living with children increased disease risk, and no difference was detectable between the Russian and Western vaccines.
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In 1991, the incidence of diphtheria in Ukraine began to rise sharply after decades of very low levels of disease. Mirroring a similar resurgence of diphtheria in neighboring Russia, the epidemic in Ukraine peaked in 1995 with 15000 cases, 80% of whom were adults between the ages of 16 and 59. In June 1994, the United States Agency for International Development (USAID) initiated a cooperative program, executed by the Program for Appropriate Technology in Health (PATH), to respond to a request from the government of Ukraine for assistance in meeting the need for massive supplies of diphtheria toxoid for adults. In 1993 and 1994, the Ukraine government had intensified its own efforts to immunize the adult population, but these efforts had no apparent effect on disease incidence. In the first quarter of 1995, the government of Ukraine adopted the consensus recommendation for a mass immunization campaign strategy after discussions at an international meeting in Kiev attended by Ukrainian experts and representatives of the World Health Organization, the US Centers for Disease Control and Prevention (CDC), USAID, and PATH. In April 1995, four southern oblasts, or provinces, the Republic of Crimea, and two cities undertook mass adult immunization campaigns. In the fall of 1995, when the usual seasonal increase in diphtheria cases was beginning again, several more oblasts launched their own campaigns. People were vaccinated without regard to any history of immunization.
Although case surveillance was good, vaccine coverage data were incomplete and estimates varied widely between and even within oblasts, making it difficult to determine what effect, if any, the campaigns were having. In addition, the use of Western vaccine instead of the more familiar Russian vaccine raised concerns about vaccine efficacy among Ukrainian health workers. The persistence of the adult diphtheria epidemic in a population previously thought to be well immunized raised questions about the number of doses needed to re-establish immunity among different age groups. There were also questions about the relationship between the adult epidemic and the epidemic among children.
Serologic studies done by the Ukrainian Ministry of Health (MOH) in collaboration with CDC [1] had demonstrated that the Western vaccine was as immunogenic as the Russian vaccine and that most adult groups needed only one booster dose (although those 30-49 years old would benefit from one or two additional doses). However, some Ukrainian scientists still had reservations about the efficacy of the vaccine, so the MOH decided to use three doses for all adults (only one dose was to come from humanitarian assistance sources).
To address some of these questions, PATH, in collaboration with the MOH, undertook a matched case-control study. The study was designed to determine whether those recently immunized were indeed protected from disease, whether multiple doses were more protective, whether contact with children (who were suspected to be poorly vaccinated in the 1980s) was related to disease, and whether there were detectable differences in protective efficacy between Western vaccines (particularly those provided by USAID) and Russian vaccines. Since factors such as age, potential exposure to other cases, and number and timing of vaccine doses were known to affect risk, a multiple re- 
Materials and Methods
The study was carried out in three locations. One was in the urban area of Lviv, a region that was not part of the organized campaigns of the first half of 1995. The second and third were in the urban and rural areas, respectively, of Zaporizhzhya city and Melitopol raion (or district), both of which were in the southeastern oblast of Zaporizhzhya. Melitopol had been the earliest focal point of the epidemic in Zaporizhska Oblast. Sixty cases and 2 matched controls for each case were identified in each site. Both cases and controls were between the ages of 16 and 59 at the index date (the date the case's diagnosis was made).
Cases. Cases were identified from polyclinic (health center) records (i.e., the register of diphtheria cases with laboratory confirmation) and had been diagnosed between January and December 1995; in Melitopol, where the epidemic started earlier and numbers were smaller, the eligibility was extended back to July 1994. All consecutive eligible cases were enrolled at each eligible polyclinic until the study quota (60) was reached. The enrolled cases represent 175% of all eligible cases in each location.
Controls. Controls were adults who, according to their polyclinic records, had not had diphtheria prior to the index date. They were selected from the polyclinic where the case was listed, using the register of all residents in the designated catchment area for that polyclinic (based on a semi-annual household census). Two controls were drawn randomly, 1 each from the household just above and just below the case in the register. This usually meant that the controls lived in either the same or an adjacent building as the case.
Data collection and analysis. Age, sex, vaccination history, date of diagnosis, and clinical course for the cases were taken from medical records at the polyclinic; the size and composition of the cases' households were taken from the polyclinic register. Age, sex, household size and composition, and vaccination history for controls were taken from the polyclinic registers. When the polyclinic register identified a control as being under the care of an employerbased clinic, the vaccination history was checked by telephone with the polyclinic holding the records. Vaccine source was noted as "USAID" when indicated as such on the record; if not so indicated, it was recorded as "other." All data were collected by local MOH staff in February 1996. A sample of 5% of controls in each of the three sites was contacted within the next 2 months by telephone or in person to verify the data in the polyclinic register. Nearly 85% of the items checked were in complete agreement with the records, while the remaining variances were generally minor. Vaccinations occurring !7 days before and at any time after the index date for cases and controls were excluded from the analysis since they cannot have been expected to have offered any protection within the time period under consideration.
Data were entered into the computer using Epi Info 5.0 (CDC, Atlanta), and descriptive statistics were carried out using SPSS-PC (SPSS, Chicago). Conditional multiple logistic regression (for matched analysis) using the EGRET software package (Cytel Software, Cambridge, MA) was done to identify independent risk factors and control for confounding variables. Relative risks approximated by the odds ratios were estimated by the method of maximum likelihood, and 95% confidence intervals were based on the standard error of the coefficient estimate and the normal approximation. Age was categorized into 10-year groups except for those 16-19 years old. Age group, number of children in the household, and number of doses were factored for the analysis, while household size was entered in the model as a continuous variable. Table 1 shows the characteristics of the study participants in terms of age, sex, and household size and composition. Cases were much more likely than controls to be 16-19 or 40-49 years old. National case data show a similar distribution of age. However, national age distribution figures for the general population suggest that younger adults were substantially underrepresented among the controls (those 16-19 years old should have represented ∼9.5% of the control group, and those 20-29 years old should have represented ∼25%). Overall, both groups were nearly 40% male and 60% female, with the proportion of women increasing with age as it does in the general population. However, women were significantly over-represented among controls (when compared with estimates based on the national age distribution in 1992) in the 40-to 49-year-old age group, while there was a very marked over-representation of women among cases in the 50-to 59-year-old age group (table 2) . A higher proportion of cases (13% vs. 7%) came from the largest households and from medium-sized households (43% vs. 28%). Similarly, cases were more likely to come from households with either young or school-age children.
Results
Cases were much less likely than controls to have been vaccinated (table 3) in the year preceding the onset of disease (the index date for controls) and were somewhat less likely to have had at least one dose since January 1990. One or two recent doses (within 1 year) were much more common among controls Among the cases, there was no apparent trend by age for a single dose of vaccine in the year prior to infection, but younger cases were much less likely to have had a second dose within the year prior to infection. Cases were twice as likely to have a record of being vaccinated before 1990, but the numbers were small, and the records for this early period were incomplete and not considered by local staff to be as reliable as those since 1990. Among those with vaccination recorded since 1990, the vast majority (86%) of controls had their most recent dose within the year preceding the index date. Cases were 5-7 times as likely to have had their most recent and next most recent dose of vaccine 2-3 years before the index date and were about four times as likely to have had their most recent dose more than 4 years before the index date (although numbers are small). There was very little difference between vaccinated cases and controls as to whether vaccine they received in 1994 or 1995 came from USAID-funded supplies or other European or Russian sources.
As seen in table 4, there were differences in vaccination coverage in the three study sites (based on the rates among the controls), with Lviv having much lower rates of recent vaccination than Zaporizhzhya and Melitopol (which participated in the April 1995 mass campaign, while Lviv's campaign occurred late in 1995). The differences are much less when considering the level of coverage with two or more doses in the year preceding the index date, although Lviv is still lower than the others. On the other hand, Lviv had much higher rates of vaccination reported before 1990, while Melitopol had no controls with such a history, suggesting either lower rates of vaccination before 1990 or weaker record-keeping. Because the epidemic (and active vaccination efforts) started in 1993 in Melitopol, it is not surprising that the proportion of vaccinated people whose most recent dose was received in 1994 or 1995 is somewhat lower there than in the other two sites. As to the source of vaccine received in general (based on controls), Melitopol was much more likely to have used vaccine provided by USAID funds.
Using conditional multiple logistic regression to control for variations in age, sex, and household size and composition, we found that cases were five times as likely as controls to have had no vaccine in the year preceding the onset of disease (table  5) . This implies an efficacy of 80% for at least one dose of vaccine in the year preceding the index date. In looking at the effect of vaccination in the 3-5 years before the year preceding the index date, it is difficult to disentangle the effects since so many people were immunized in the most recent year. The apparent 3-fold risk associated with lack of vaccination since 1992 drops to 1.0 when it is adjusted for prior-year vaccination, suggesting that the protective effect of vaccine given since 1992 is largely or entirely due to very recent vaccinations (i.e., those received in the year preceding the index date). There is a clear dose relationship for doses given in the year preceding the index date, with vaccine efficacy of nearly 70% for a single dose and 190% for those receiving two or three doses in the most recent year. The dose relationship is less clear when considering all doses given since January 1992, perhaps because most of those who received three doses had their first dose in the earlier part of the period.
Using the logistic regression model and adjusting for vac- cination history in the year immediately preceding the index dates, it was possible to identify several risk factors for adult diphtheria infection independent of vaccination (table 6). Using the 50-to 59-year-old age group (who had the lowest disease risk) as the reference group, we found that those 16-19 years old had a very high relative risk, and 40-to 49-year-old persons had the next highest risk level. Contrary to the trends seen in national case data, showing women with much higher incidence, these data show only a slightly elevated risk for women once they are adjusted for age, vaccination history, and household size and composition. However, given the small numbers in each age group and the skewed sex distribution in the upper two age categories, it was not possible to disentangle the potential effects of selection bias on the sex-related risk. The total number of people living in the household is associated with a modest increase in risk that rises to 12-fold with у4 people. In addition, there is a modest, not quite significant increase in risk associated with having 1 or 2 children who were !5 years old or 1 school-age child in the household. With у2 schoolage children in the household, the risk is significant and 12-fold.
Discussion
The level of efficacy for diphtheria vaccine shown in this study (70%-90%, depending on the no. and recency of doses) is consistent with the vaccine efficacy and adult seroconversion levels reported elsewhere [3, 4] . Since the vaccine is not 100% effective, it is not surprising that some cases were infected despite vaccination. It is interesting to note that vaccinated cases were much more likely than vaccinated controls to have received their vaccine prior to the introduction of mass campaigns and Western vaccines in 1994. Since immunization efforts prior to the campaigns were directed at groups considered to be at higher risk of infection because of occupational exposures (a factor not measurable in the data sources available in this study), the association with earlier vaccination may be a result of confounding (by occupational exposure).
For the period when both Western and Russian vaccines were in use (1994 forward), the data show equivalent experience between cases and controls with regard to USAID-supplied vaccine versus other sources. Polyclinic records, however, were not reliable in distinguishing between other donated Western vaccines and Russian vaccines purchased by oblasts. The lower level of efficacy of doses prior to 1994 may be due just to waning immunity over time. This would support the finding that vaccine-induced immunity may not last nearly as long as had been previously assumed [3] .
The recommendation that only people 30-49 years old might need more than one dose, while younger adults might be protected with just one dose, which was made on the basis of the CDC-government of Ukraine serostudy cited earlier, was not borne out by these data. Even when the data were adjusted for age, the protective benefit of a second dose was statistically significant. When interaction terms of age and dose were entered in the logistic regression model, they were not suggestive of any substantial effect ( ). The effect of multiple doses P 1 .4 is generally difficult to interpret without knowing whether and when a primary series was given. Controls were half as likely as cases to have any record of vaccination prior to 1990, but this may be due to more effort having been made to ascertain the full immunization history of cases.
The extremely elevated risks for persons 16-19 years old may have to be explained by several factors. This age group was significantly under-represented among the controls, perhaps because they (and to a lesser extent, those in the 20-to 29-yearold age group) are more mobile (as students or young workers) and are less likely to register with the local polyclinic or to be identified during the household census. As noted earlier, they were also less likely to have had more than one dose of vaccine in recent years. Members of this age group may have missed scheduled childhood booster doses during the 1980s and early 1990s when childhood vaccination coverage rates dropped below 50% in Ukraine [6] . A larger study with better data on childhood vaccination history, which is kept at the pediatric clinics and often not transferred when adolescents switch to adult services at age 16, will be needed to clarify why this age group has experienced such elevated rates of diphtheria infection. National incidence data [5] and other studies [6] have suggested that women may be at greater risk than men. Two explanations for this are that women may have more exposure through their roles as care givers to children and ill family members, and men are more likely to receive vaccine boosters during military service. In the bivariate analysis in this study, women in various age groups had increased disease risks ranging from 1.1 to 4.0, except for 40-to 49-year old women, who had a lower risk than men. The apparent increased risk for women was reduced to a modest, nonsignificant elevation once age, recent vaccination history, household size, and exposure to children were controlled for, thereby lending weight to the suggested explanations. However, if women were over-represented in the control group, as appears to be the case, it is not possible to rule out sex as an independent risk factor. Such over-representation might have occurred, for example, if women were more likely to be listed in polyclinic registers (from which controls were drawn) because they are less likely than men to move around or live away from home periodically and get dropped from the registers.
Since many Western countries have low levels of protective immunity against diphtheria among adults, similar to the case in Ukraine, it has been suggested that this epidemic took hold in Ukraine and Russia because of the drop in childhood vaccination levels during the 1980s and early 1990s [6] . Because many diphtheria infections are subclinical or are not identified as diphtheria, it was not possible to measure adult exposure to infected children directly in this study. However, the increased risk associated with the presence of children in the household (especially school-age children, who would have been eligible for their primary diphtheria-tetanus toxoids-pertussis series in the 1980s when coverage levels in Ukraine dropped below 50%) lends weight to this hypothesis. While one might have expected infants and toddlers to be more efficient in spreading respiratory infections, it is notable that the risk was actually higher for the older children. This stronger association is not likely to be explained by greater exposure at school, since even toddlers attend public daycare facilities in high numbers in Ukraine. The increased risk of disease experienced by men and women living with school-age children and, to a lesser extent, younger children indicates the importance of ensuring that children receive appropriate booster doses and a primary series of immunizations.
There are certain limitations in the study that suggest the need for caution in interpreting the findings. The data on vaccine history prior to 1990 were incomplete, possibly unreliable (given some anecdotal reports of falsified immunization records during the 1980s), and quite variable across the three study sites. The number of people with three doses of vaccine in recent years was small, so dose relationships were unstable. The high level of participation in the recent campaigns made it difficult to distinguish possible protective effects of earlier doses. Also, it was not possible to distinguish with certainty the origins of the various vaccines in use in 1994-1995, thus preventing a definitive answer to questions about the effectiveness of vaccines of different strengths.
Given the limitations listed above, it is clear that recent vaccination with one or more doses of diphtheria toxoid (whether Russian or Western) is highly protective among adults. Two doses provide substantially more protection than one, regardless of age. Recently given vaccine provides greater protection in an epidemic than vaccine given several years earlier, although vaccination within 3-4 years before the epidemic provides some protective effect. These findings suggest that MOH officials, health workers, and international donor and health agencies can feel reassured that the massive efforts to vaccinate the adult population in Ukraine were responsible for substantial disease reduction and the saving of many lives.
